Generar recomendaciones basadas en la mejor evidencia disponible acerca del manejo
clínico de personas con Enfermedad Pulmonar Obstructiva Crónica (EPOC). Con especial enfoque en el apoyo a los equipos de salud en la toma de decisiones respecto al tratamiento y derivación de las personas con
EPOC....
Ergan, B;
Oczkowski, S;
Rochwerg, B;
Carlucci, A;
Chatwin, M;
Clini, E;
Elliott, M;
Gonzalez-Bermejo, J;
Hart, N;
Lujan, M;
Nasilowski, J;
Nava, S;
Pepin, J. L;
Pisani, L;
Storre, J. H;
Wijkstra, P;
Tonia, T;
Boyd, J;
Scala, R;
Windisch, W.
While the role of acute non-invasive ventilation (NIV) has been shown to improve outcome in acute life-threatening hypercapnic respiratory failure in COPD, the evidence of clinical efficacy of long-term home NIV (LTH-NIV) for management of COPD is less. This document provides evidence-based recommendatio...
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD
(which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help
people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce
symptoms, improve q...
This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic
obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic
resistance....
This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance. This guideline includes recommendations on: treatment; reassessment; referral and seeking specialist ...
Wedzicha, JA;
Calverley, PMA;
Albert, RK;
Anzueto, A;
Criner, GJ;
Hurst, JR;
Miravitlles, M;
Papi, A;
Rabe, KF;
Rigau, D;
Sliwinski, P;
Tonia, T;
Vestbo, J;
Wilson, KC;
Krishnan, JA.
This document provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society.Comprehensive evidence syntheses were performed to summarise al...
Adrenergic beta-2 Receptor Agonists/therapeutic use,
Aminopyridines/therapeutic use,
Benzamides/therapeutic use,
Cyclopropanes/therapeutic use,
Fluoroquinolones/therapeutic use,
Macrolides/therapeutic use,
Muscarinic Antagonists/therapeutic use,
Phosphodiesterase 4 Inhibitors/therapeutic use,
Disease Progression,
Pulmonary Disease, Chronic Obstructive,
Pulmonary Disease, Chronic Obstructive/drug therapy,
Pulmonary Disease, Chronic Obstructive/physiopathology,
Secondary Prevention/standards,
Adrenergic beta-2 Receptor Agonists,
Aminopyridines,
Benzamides,
Cyclopropanes,
Fluoroquinolones,
Macrolides,
Muscarinic Antagonists,
Phosphodiesterase 4 Inhibitors
Miravitlles, M;
Soler-Cataluña, J. J;
Calle, M;
Molina, J;
Almagro, P;
Quintano, J. A;
Trigueros, J. A;
Cosío, B. G;
Casanova, C;
Antonio Riesco, J;
Simonet, P;
Rigau, D;
Soriano, J. B;
Ancochea, J.
La enfermedad pulmonar obstructiva crónica (EPOC) presenta una gran heterogeneidad clínica, por lo que su tratamiento se debe individualizar según el nivel de riesgo y el fenotipo. La Guía española de la EPOC (GesEPOC) estableció por primera vez en 2012 unas pautas de tratamiento farmacológico bas...
Jouneau, S;
Dres, M;
Guerder, A;
Bele, N;
Bellocq, A;
Bernady, A;
Berne, G;
Bourdin, A;
Brinchault, G;
Burgel, P. R;
Carlier, N;
Chabot, F;
Chavaillon, J. M;
Cittee, J;
Claessens, Y. E;
Delclaux, B;
Deslée, G;
Ferré, A;
Gacouin, A;
Girault, C;
Ghasarossian, C;
Gouilly, P;
Gut-Gobert, C;
Gonzalez-Bermejo, J;
Jebrak, G;
Le Guillou, F;
Léveiller, G;
Lorenzo, A;
Mal, H;
Molinari, N;
Morel, H;
Morel, V;
Noel, F;
Pégliasco, H;
Perotin, J. M;
Piquet, J;
Pontier, S;
Rabbat, A;
Revest, M;
Reychler, G;
Stelianides, S;
Surpas, P;
Tattevin, P;
Roche, N.
Chronic obstructive pulmonary disease (COPD) is the chronic respiratory disease with the most important burden on public health in terms of morbidity, mortality and health costs. For patients, COPD is a major source of disability because of dyspnea, restriction in daily activities, exacerbation, risk of ...
Miravitlles, Marc;
Soler-Cataluña, Juan José;
Calle, Myriam;
Molina, Jesús;
Almagro, Pere;
Quintano, José Antonio;
Trigueros, Juan Antonio;
Cosío, Borja G;
Casanova, Ciro;
Riesco, Juan Antonio;
Simonet, Pere;
Rigau, David;
Soriano, Joan B;
Ancochean, Julio.
La enfermedad pulmonar obstructiva crónica (EPOC) presenta una gran heterogeneidad clínica, por lo que su tratamiento se debe individualizar según el nivel de riesgo y el fenotipo. La Guía Española de la EPOC (GesEPOC) estableció por primera vez en 2012 unas pautas de tratamiento farmacológico bas...
Barreiro, E;
Bustamante, V;
Cejudo, P;
Gáldiz, J. B;
Gea, J;
Lucas, P. de;
Martínez-Llorens, J;
Ortega, F;
Puente-Maestu, L;
Roca, J;
González Moro, J. M Rodríguez.
La disfunción muscular de pacientes con enfermedad pulmonar obstructiva crónica (EPOC) constituye una de las comorbilidades más importantes, con repercusiones negativas en su capacidad de ejercicio y calidad de vida. En la presente normativa se ha resumido la literatura publicada más recientemente so...
Muscle Weakness/therapy,
Pulmonary Disease, Chronic Obstructive,
Ghrelin/therapeutic use,
Steroids/therapeutic use,
Growth Hormone-Releasing Hormone/therapeutic use,
Helium/therapeutic use,
Oxygen/therapeutic use,
Breathing Exercises,
Electrodiagnosis,
Exercise Therapy,
Nutritional Support,
Spirometry
